METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST
Methods for neutralizing and/or removing human GM-CSF in a subject in need thereof, comprising administering to the subject CAR-T cells having a GM-CSF gene knockout (GM-CSF k/o CAR-T cells) are provided. Also provided are methods for GM-CSF gene inactivation or GM-CSF knockout (KO) in a cell comprising targeted genome editing or GM-CSF gene silencing. Methods for preventing/treating immunotherapy-related toxicity, comprising administering to the subject CAR-T cells having a GM-CSF gene inactivation or GM-CSF knockout (GM-CSF k/o CAR-T cells), wherein the GM-CSF gene is inactivated or knocked out and/or a recombinant GM-CSF antagonist are provided. Methods for reducing a level of a cytokine or chemokine other than GM-CSF in a subject having immunotherapy-related toxicity comprising administering to the subject a recombinant hGM-CSF antagonist are provided. Also provided are methods for treating or preventing immunotherapy-related toxicity in a subject, comprising administering to the subject chimeric antigen receptor-expressing T-cells (CAR-T cells), the CAR-T cells having a GM-CSF gene knockout (GM-CSF k/o CAR-T cells). Methods for preventing or reducing blood-brain barrier disruption in a subject treated with immunotherapy, the method comprising administering CAR-T cells having a GM-CSF gene knockout (GM-CSF k/o CAR-T cells) to the subject, also are provided.
1 . A method for treating a subject having cancer, the method comprising:
a) administering a therapeutically effective amount of a recombinant hGM-CSF antagonist to the subject, wherein the recombinant hGM-CSF antagonist is anti-hGM-CSF antibody lenzilumab; and
b) administering anti-CD19 CAR-T cells to the subject.
2 . The method of claim 1 , wherein the anti-hGM-CSF antibody lenzilumab is administered at a dose of from 600 mg to 1800 mg, wherein the dose of 600 mg is administered over a 1-hour IV infusion and the dose of1800 mg is administered over a 2-hour IV infusion.
3 . The method of claim 1 , wherein the anti-hGM-CSF antibody lenzilumab is administered at a dose of 600 mg every 8 hours for a total of three doses over 24 hours for one day.
4 . The method of claim 1 , wherein the anti-hGM-CSF antibody lenzilumab is administered at a dose of 800 mg every 12 hours for a total of two doses over 24 hours for one day.
5 . The method of claim 1 , wherein the GM-CSF antagonist is administered at a dose of 1800 mg as a single dose over a two-hour IV infusion.
6 . The method of claim 1 , wherein treatment achieves an objective response rate of at least 80%.
7 . The method of claim 6 , wherein the objective response rate is a complete response or partial response.
8 . The method of claim 1 , wherein the recombinant hGM-CSF antagonist lenzilumab is administered prior to administration of the anti-CD19 CAR-T cells or the anti-CD19 CAR-T cells are administered prior to administration of the anti-hGM-CSF antibody lenzilumab.
9 . The method of claim 8 , wherein the anti-CD19 CAR-T cells are administered 2-24 hours after the administration of the anti-hGM-CSF antibody lenzilumab.
10 . The method of claim 8 , wherein the anti-hGM-CSF antibody lenzilumab is administered 2-24 hours after the administration of the anti-CD19 CAR-T cells.
11 . The method of claim 1 , wherein tumor burden at four weeks after treatment is a complete response of no tumor detection compared to the baseline tumor burden.
12 . The method of claim 1 , wherein tumor burden at four weeks after treatment is a partial response of ≥50% reduction in SPD compared to the baseline tumor burden.
13 . The method of claim 2 , wherein the subject has no cytokine release syndrome (CRS) at or above grade 3 after treatment, wherein administration of the anti-hGM-CSF antibody lenzilumab is at a dose of 600 mg.
14 . The method of claim 2 , wherein the subject has no cytokine release syndrome (CRS) at or above grade 2 or neurotoxicity at or above grade 1 after treatment, wherein administration of the anti-hGM-CSF antibody lenzilumab is at a dose of 1800 mg.
15 . The method of claim 2 , wherein the subject has cytokine release syndrome (CRS) and neurotoxicity below grade 2 after treatment and a complete response, wherein the complete response is a toxicity-free complete response and administration of the anti-hGM-CSF antibody lenzilumab is at a dose of 1800 mg.
16 . The method of claim 15 , wherein the rate of toxicity-free complete response is improved by more than 50% compared to a patient who is administered CAR-T cells without the anti-hGM-CSF antibody lenzilumab.
17 . The method of claim 1 , wherein administration of the anti-hGM-CSF antibody lenzilumab dose dependently reduces systemic inflammation that occurs after CAR-T cell administration.
18 . The method of claim 17 , wherein the reduced systemic inflammation comprises reduced levels of CRS, ferritin, and SAA.
19 . The method of claim, wherein the reduced CRS comprises decreased levels of myeloid cytokines, wherein the myeloid cytokines are IL-6, IL-8, MCP-1, and/or IP-10 (CXCL-10) and/or a reduction of release of IL-2.
20 . The method of claim, wherein the reduced CRS comprises decreased levels of acute T cell cytokines, wherein the acute T cell cytokines are TNF-a, IL-12p40, INF-γ, and/or perforin.
21 . The method of claim 1 , further comprising administering a second dose of the anti-hGM-CSF antibody lenzilumab at day 4 or 5 after administration of the anti-CD19 CAR-T cells.
22 . The method of claim 1 , wherein administration of the anti-hGM-CSF antibody lenzilumab reduces or delays differentiation of anti-CD19 CAR-T cells preventing CAR-T cell exhaustion and CAR-T cell activation induced cell death.
23 . A method for reducing or eliminating incidence or the severity of immunotherapy-related toxicity in a subject treated for cancer, the method comprising:
a) administering a recombinant hGM-CSF antagonist to the subject, wherein the recombinant hGM-CSF antagonist is anti-hGM-CSF antibody lenzilumab; and
b) administering anti-CD19 CAR-T cells to the subject after administration of the anti-hGM-CSF antibody lenzilumab.
24 . The method of claim 23 , wherein the anti-hGM-CSF antibody lenzilumab is administered at a dose of from 600 mg to 1800 mg, wherein the dose of 600 mg is administered over a 1-hour IV infusion and the dose of1800 mg is administered over a 2-hour IV infusion.
25 . The method of claim 23 , wherein the anti-hGM-CSF antibody lenzilumab is administered at a dose of 600 mg every 8 hours for a total of three doses over 24 hours for one day.
26 . The method of claim 23 , wherein the anti-hGM-CSF antibody lenzilumab is administered at a dose of 800 mg every 12 hours for a total of two doses over 24 hours for one day.
27 . The method of claim 23 , wherein the GM-CSF antagonist is administered at a dose of 1800 mg as a single dose over a 2-hour IV infusion.
28 . The method of claim 23 , wherein treatment achieves an objective response rate of at least 80%.
29 . The method of claim 28 , wherein the objective response rate is a complete response or partial response.
30 . The method of claim 23 , wherein the anti-CD19 CAR-T cells are administered 2-24 hours after the administration of the anti-hGM-CSF antibody lenzilumab or the anti-hGM-CSF antibody lenzilumab is administered 2-24 hours after the administration of the anti-CD19 CAR-T cells.
31 . The method of claim 23 , wherein tumor burden at four weeks after treatment is a complete response of no tumor detection compared to the baseline tumor burden.
32 . The method of claim 23 , wherein tumor burden at four weeks after treatment is a partial response of >50% reduction in SPD compared to the baseline tumor burden.
33 . The method of claim 24 , wherein the immunotherapy-related toxicity comprises cytokine release syndrome (CRS) and/or neurotoxicity (NT) and the subject has no CRS or NT at or above grade 3 after treatment, wherein administration of the anti-hGM-CSF antibody lenzilumab is at a dose of 600 mg.
34 . The method of claim 24 , wherein the subject has no cytokine release syndrome (CRS) above grade 2 or NT at or above grade 1 after treatment, wherein administration of the anti-hGM-CSF antibody lenzilumab is at a dose of 1800 mg.
35 . The method of claim 24 , wherein the subject has cytokine release syndrome (CRS) and neurotoxicity below grade 2 after treatment and a complete response (toxicity-free complete response), wherein administration of the anti-hGM-CSF antibody lenzilumab is at a dose of 1800 mg.
36 . The method of claim 35 , wherein the rate of toxicity-free complete response is improved by more than 50% compared to patients receiving CAR-T without the anti-hGM-CSF antibody.
37 . The method of claim 23 , wherein administration of the anti-hGM-CSF antibody lenzilumab dose dependently reduces systemic inflammation that occurs after CAR-T administration.
38 . The method of claim 37 , wherein the reduced systemic inflammation comprises reduced levels of CRS, ferritin, and SAA.
39 . The method of claim 38 , wherein the reduced CRS comprises decreased levels of myeloid cytokines, wherein the myeloid cytokines are IL-6, IL-8, MCP-1, and/or IP-10 (CXCL-10) and/or a reduction of release of IL-2.
40 . The method of claim 38 , wherein the reduced CRS comprises decreased levels of acute T cell cytokines, wherein the acute T cell cytokines are TNF-a, IL-12p40, INF-γ, and/or perforin.
41 . The method of claim 23 , further comprising administering a second dose of the anti-hGM-CSF antibody lenzilumab at day 4 or 5 after administration of the anti-CD19 CAR-T cells.
42 . The method of claim 23 , wherein administration of the anti-hGM-CSF antibody lenzilumab reduces or delays differentiation of anti-CD19 CAR-T cells preventing CAR-T cell exhaustion and CAR-T cell activation induced cell death.
43 . A method for delaying or preventing adverse immunotherapy-related neurologic events in a subject treated for cancer with anti-CD19 CAR-T cell therapy, the method comprising:
a) administering a recombinant hGM-CSF antagonist to the subject, wherein the recombinant hGM-CSF antagonist is anti-hGM-CSF antibody lenzilumab; and
b) administering anti-CD19 CAR-T cells to the subject after administration of the anti-hGM-CSF antibody lenzilumab
44 . The method of claim 43 , wherein the anti-hGM-CSF antibody lenzilumab is administered at a dose of from 600 mg to 1800 mg, wherein the dose of 600 mg is administered over a 1-hour IV infusion and the dose of1800 mg is administered over a 2 hour IV infusion.
45 . The method of claim 43 , wherein the anti-hGM-CSF antibody lenzilumab is administered at a dose of 600 mg every 8 hours for a total of three doses over 24 hours for one day.
46 . The method of claim 43 , wherein the anti-hGM-CSF antibody lenzilumab is administered at a dose of 800 mg every 12 hours for a total of two doses over 24 hours for one day.
47 . The method of claim 43 , wherein the GM-CSF antagonist is administered at a dose of 1800 mg as a single dose over a 2-hour IV infusion.
48 . The method of claim 43 , wherein treatment achieves an objective response rate of at least 80%.
49 . The method of claim 48 , wherein the objective response rate is a complete response or partial response.
50 . The method of claim 43 , wherein the anti-CD19 CAR-T cells are administered 2-24 hours after the administration of the anti-hGM-CSF antibody lenzilumab or the anti-hGM-CSF antibody lenzilumab is administered 2-24 hours after the administration of the anti-CD19 CAR-T cells.
51 . The method of claim 43 , wherein tumor burden at four weeks after treatment is a complete response of no tumor detection compared to the baseline tumor burden.
52 . The method of claim 43 , wherein tumor burden at four weeks after treatment is a partial response of ≥50% reduction in SPD compared to the baseline tumor burden.
53 . The method of claim 52 , wherein the subject has no cytokine release syndrome (CRS) at or above grade 3 after treatment, wherein administration of the anti-hGM-CSF antibody lenzilumab is at a dose of 600 mg.
54 . The method of claim 52 , wherein the subject has no cytokine release syndrome (CRS) at or above grade 2 or neurotoxicity at or above grade 1 after treatment. wherein administration of the anti-hGM-CSF antibody lenzilumab is at a dose of 1800 mg.
55 . The method of claim 52 , wherein the subject has cytokine release syndrome (CRS) and neurotoxicity below grade 2 and a complete response after treatment (toxicity-free complete response), wherein administration of the anti-hGM-CSF antibody lenzilumab is at a dose of 1800 mg.
56 . The method of claim 55 , wherein the rate of toxicity-free complete response is improved by more than 50% compared to patients receiving CAR-T without the anti-hGM-CSF antibody.
57 . The method of claim 43 , wherein administration of the anti-hGM-CSF antibody lenzilumab dose dependently reduces systemic inflammation that occurs after CAR-T administration.
58 . The method of claim 57 , wherein the reduced systemic inflammation comprises reduced levels of CRS, ferritin, and SAA.
59 . The method of claim 58 , wherein the reduced CRS comprises decreased levels of myeloid cytokines, wherein the myeloid cytokines are IL-6, IL-8, MCP-1, and/or IP-10 (CXCL-10) and/or a reduction of release of IL-2.
60 . The method of claim 58 , wherein the reduced CRS comprises decreased levels of acute T cell cytokines, wherein the acute T cell cytokines are TNF-a, IL-12p40, INF-G, and/or perforin.
61 . The method of claim 43 , further comprising administering a second dose of the anti-hGM-CSF antibody lenzilumab at day 4 or 5 after administration of the anti-CD19 CAR-T cells.
62 . The method of claim 43 , wherein administration of the anti-hGM-CSF antibody lenzilumab reduces or delays differentiation of anti-CD19 CAR-T cells preventing CAR-T cell exhaustion and CAR-T cell activation induced cell death.
63 . The method of claim 43 , wherein the adverse immunotherapy-related neurologic events are a state of confusion, tremor and/or encephalopathy.
64 . The method of claim 13 , further comprising administering a therapeutically effective amount of an anti-IL-6 receptor monoclonal antibody and/or a steroid.
65 . The method of claim 14 , further comprising administering a therapeutically effective amount of an anti-IL-6 receptor monoclonal antibody and/or a steroid.
66 . The method of claim 15 , further comprising administering a therapeutically effective amount of an anti-IL-6 receptor monoclonal antibody and/or a steroid.
67 . The method of claim 33 , further comprising administering a therapeutically effective amount of an anti-IL-6 receptor monoclonal antibody and/or a steroid.
68 . The method of claim 34 , further comprising administering a therapeutically effective amount of an anti-IL-6 receptor monoclonal antibody and/or a steroid.
69 . The method of claim 35 , further comprising administering a therapeutically effective amount of an anti-IL-6 receptor monoclonal antibody and/or a steroid.
70 . The method of claim 53 , further comprising administering a therapeutically effective amount of an anti-IL-6 receptor monoclonal antibody and/or a steroid.
71 . The method of claim 54 , further comprising administering a therapeutically effective amount of an anti-IL-6 receptor monoclonal antibody and/or a steroid.
72 . The method of claim 55 , further comprising administering a therapeutically effective amount of an anti-IL-6 receptor monoclonal antibody and/or a steroid.